Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in.

TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox in adults considered at elevated risk of infection. The decision broadens the vaccine’s application beyond its prior scope and supports its role in public health preparedness for emerging infectious threats. The company highlighted the approval as evidence of the strength and range of its medical countermeasure portfolio and emphasized continued engagement with global regulatory agencies to expand access to protective and life-saving medical solutions.

Separately, on April 29, Emergent BioSolutions Inc. (NYSE:EBS) announced a multi-year collaboration with SAB Biotherapeutics focused on development and manufacturing support for SAB-142, a clinical-stage candidate for autoimmune type 1 diabetes. The agreement is valued at roughly $50 million, with about $36 million tied to potential regulatory approval and future milestone achievements.Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization

Under the partnership, EBS will provide full-scale development and manufacturing services aligned with current good manufacturing practices, including process optimization, scale-up activities, technology transfer, analytical method support, and clinical supply production. Commercial manufacturing support is also included, contingent on eventual regulatory clearance of the program.

Emergent BioSolutions Inc. (NYSE:EBS) is a global life sciences company that develops and manufactures vaccines, therapeutics, and other medical countermeasures for public health threats like infectious diseases, chemical/biological agents, and opioid overdoses.

While we acknowledge the potential of EBS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.

View Comments